BioTime CEO Dr. Michael West Presents At GTCbio Advances In Stem Cell Discoveries Meeting "Embryomics: Implications For Regenerative Medicine"

Main Category: Stem Cell Research
Article Date: 28 Oct 2008 - 9:00 PDT

email to a friend   printer friendly   view / write opinions

BioTime, Inc. (OTCBB:BTIM) Chief Executive Officer Michael West, Ph.D. will deliver a presentation this morning at the GTCbio Advances in Stem Cell Discoveries meeting in San Francisco. Dr. West's presentation is titled "Embryomics: Implications for Regenerative Medicine."

This year's conference will focus on cutting-edge information on developments in all areas of stem cell research, including the biology, medicine, applications, regulation, and business of Stem Cells. Dr. West's presentation will include a description of BioTime's stem cell research programs that are focused on opportunities for near-term revenues in the development and marketing of cell lines, growth and differentiation factors, antibodies and a relational database and research tool that can be accessed at BioTime's stem cell website embryome.com.

Dr. West will announce the launch of two new cell line products and will present data on their unique properties and potential utility in regenerative medicine. The molecular markers of these lines are consistent with two types of human neural crest cells that have promise for the treatment of numerous diseases such as cranial-facial disorders involving certain tissues of the face, dentition, and neck, and disorders of the peripheral nervous system. Information about these cell lines is now available online at http://www.embryome.com, and the cells themselves are now available for purchase for research purposes only through the same website.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions, and technology for use in surgery, emergency trauma treatment and other applications. BioTime's lead product Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements.

BioTime has recently entered the field of regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc. where it plans to develop new medical and research products using embryonic stem cell technology. Additional information about BioTime can be found on the web at http://www.biotimeinc.com. Hextend®, PentaLyte®, HetaCool®, EmbryomicsTM, ESpyTM, and ESpanTM, are trademarks of BioTime, Inc.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

Source
Judith Segall
BioTime, Inc.